SCHEMBL2932295

SCHEMBL2932295

CC(=O)Nc1ccc(CNC(=O)O)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.73
PPID Q08752 1/20 0.60
NR1H4 Q96RI1 2/20 0.59
EPHX2 P34913 1/20 0.59
NPC1 O15118 4/20 0.59
TDP1 Q9NUW8 1/20 0.57
L3MBTL1 Q9Y468 2/20 0.56
LMNA P02545 1/20 0.55
KMT2A Q03164 5/20 0.54
MEN1 O00255 3/20 0.54
RAB9A P51151 3/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
TP53 P04637 1/20 0.54
HPGD P15428 1/20 0.54
HTT P42858 1/20 0.53
NAPRT Q6XQN6 1/20 0.53
HSD17B10 Q99714 1/20 0.53
TSHR P16473 2/20 0.53
MAPT P10636 2/20 0.52
CA12 O43570 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3735282 0.89 PTPN1 (0.72) PTPN1PPIDNR1H4EPHX2NPC1
SCHEMBL17979590 0.86 NPC1 (0.59) PTPN1NPC1L3MBTL1KMT2AMEN1
SCHEMBL21849033 0.84 PTPN1 (0.66) PTPN1PPIDNR1H4EPHX2NPC1
SCHEMBL25598493 0.84 PTPN1 (0.66) PTPN1PPIDNR1H4EPHX2NPC1
SCHEMBL6564248 0.82 NPC1 (0.56) PTPN1PPIDNPC1L3MBTL1KMT2A
SCHEMBL11533429 0.82 CYP2C9 (0.65) NPC1LMNAKMT2AMEN1RAB9A
SCHEMBL8502917 0.82 PTPN1 (0.72) PTPN1NR1H4EPHX2L3MBTL1LMNA
SCHEMBL1253488 0.81 PTPN1 (0.62) PTPN1PPIDNR1H4EPHX2NPC1
SCHEMBL12524668 0.81 PTPN1 (0.62) PTPN1PPIDNR1H4EPHX2NPC1
SCHEMBL694352 0.81 NPC1 (0.53) PTPN1NR1H4NPC1TDP1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1836163-B1 PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN NOVARTIS AG (CH) 2010-09-22 EP disclosed
US-20100087427-A1 PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN BREITENSTEIN WERNER 2010-04-08 US disclosed
CN-101115715-A Pyrrolidine derivatives for the treatment of diseases associated with renin activity NOVARTIS AG (CH) 2008-01-30 CN disclosed
EP-1836163-A2 PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN Novartis AG (CH) 2007-09-26 EP disclosed
WO-2007047575-A2 PHARMACOLOGICAL TREATMENTS FOR SLEEP-RELATED BREATHING DISORDERS THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2007-04-26 WO disclosed
WO-2006066896-A2 PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN NOVARTIS AG (CH) 2006-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087427-A1 PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN REN, ACE, PEPD PTPN1 1980/4885PPID 111/4885NR1H4 712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.